Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2019
August 30, 2019 at 11:43 am
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was CNY 0 compared to CNY 180.903 million a year ago. Sales was CNY 173.982 million compared to CNY 0 a year ago. Sales was CNY 173.982 million compared to CNY 180.903 million a year ago. Operating loss was CNY 11.068 million compared to operating Income of CNY 5.888 million a year ago. Net loss was CNY 9.373 million compared to net income of CNY 1.028 million a year ago. Basic loss per share from continuing operations was CNY 0.0091 compared to basic earnings per share from continuing operations of CNY 0.001 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
